On April 10th, Redeye will organize an investor specialist event focusing on late-stage drugs aimed to treat colorectal cancer. Isofol Medical, along with Pledpharma, will present future development plans, upcoming milestones, pivotal study design and what obstacles remains in order be granted market authorisation. Moderating analysts will be Klas Palin and Arvid Necander.
Theme-Lunch Colorectal Cancer with Isofol Medical and Pledpharma
Date: 10th of April, 12:00-13:30
Location: Redeye Salonger, Stockholm
Adress: Mäster Samuelagatn 42, 10tr
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB (publ)
Phone: +46 (0)707 646 500
About arfolitixorin (Modufolin®)
Arfolitixorin (Modufolin®) is a new drug developed to increase the efficacy of the cytotoxic agent 5-fluorouracil (5-FU) and as a rescue drug after high-dose methotrexate treatment. The active ingredient in arfolitixorin (Modufolin®), [6R]-5,10-methylenetetrahydrofolate, is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. Arfolitixorin (Modufolin®) is suitable for all patients irrespective of their capacity to activate folates since it does not require metabolic activation to exert its effect.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a drug development company within the field of oncology developing arfolitixorin (Modufolin®), primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer). Through a worldwide exclusive license agreement, Isofol holds the rights to develop and commercialise arfolitixorin (Modufolin®) within oncology with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.